摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-4-prop-2-ynyloxy-5-trifluoromethylpyrimidine | 910780-64-2

中文名称
——
中文别名
——
英文名称
2-chloro-4-prop-2-ynyloxy-5-trifluoromethylpyrimidine
英文别名
2-Chloro-4-prop-2-ynyloxy-5-trifluoromethyl-pyrimidine;2-chloro-4-prop-2-ynoxy-5-(trifluoromethyl)pyrimidine
2-chloro-4-prop-2-ynyloxy-5-trifluoromethylpyrimidine化学式
CAS
910780-64-2
化学式
C8H4ClF3N2O
mdl
——
分子量
236.581
InChiKey
OEJQOXYJAYYSRB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    2-chloro-4-prop-2-ynyloxy-5-trifluoromethylpyrimidine4-甲磺酰基苯胺盐酸 作用下, 以 1,4-二氧六环乙腈 为溶剂, 反应 18.0h, 以31%的产率得到(4-Methanesulphonylphenyl)(4-prop-2-ynyloxy-5-trifluoromethylpyrimidin-2-yl)amine
    参考文献:
    名称:
    SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE
    摘要:
    该发明涉及公式(I)的磺酮取代苯胺吡啶衍生物,其制备方法,以及作为治疗各种疾病的药物的用途。
    公开号:
    US20110251222A1
  • 作为产物:
    描述:
    2-丙炔-1-醇2,4-二氯-5-三氟甲基嘧啶 在 sodium hydride 作用下, 以 乙醚乙腈 、 mineral oil 为溶剂, 以13%的产率得到2-chloro-4-prop-2-ynyloxy-5-trifluoromethylpyrimidine
    参考文献:
    名称:
    SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE
    摘要:
    该发明涉及公式(I)的磺酮取代苯胺吡啶衍生物,其制备方法,以及作为治疗各种疾病的药物的用途。
    公开号:
    US20110251222A1
点击查看最新优质反应信息

文献信息

  • N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
    申请人:Luecking Ulrich
    公开号:US20060229325A1
    公开(公告)日:2006-10-12
    This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    本发明涉及通式(I)的嘧啶衍生物,其中Q,R1,R2,R3,R4,R5,X和m的含义如描述中所含,作为细胞周期蛋白依赖性激酶和VEGF受体酪氨酸激酶的抑制剂,它们的生产以及它们作为治疗各种疾病的药物的用途。
  • N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
    申请人:Schering AG
    公开号:US07456191B2
    公开(公告)日:2008-11-25
    This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    本发明涉及通式(I)的嘧啶衍生物,其中Q、R1、R2、R3、R4、R5、X和m的含义如说明书所述,作为细胞周期蛋白依赖性激酶和VEGF受体酪氨酸激酶的抑制剂,它们的制备以及它们作为治疗各种疾病的药物的用途。
  • N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
    申请人:Bayer Schering Pharma Aktiengesellschaft
    公开号:EP1861378A1
    公开(公告)日:2007-12-05
  • US7456191B2
    申请人:——
    公开号:US7456191B2
    公开(公告)日:2008-11-25
  • US8802686B2
    申请人:——
    公开号:US8802686B2
    公开(公告)日:2014-08-12
查看更多